JAK-IN-33

Cat. No.:	HY-157011
CAS No.:	3032404-49-9
Molecular Formula:	$C_{24}H_{27}N_5O_5$
Molecular Weight:	465.5
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JAK-IN-33 (compound 3 (R)) is a JAK inhibitor[1].
In Vitro	JAK-IN-33 can be effectively applied in blood[1]. JAK-IN-33 (59 μM, 40 h) can significantly reduce the elevation of GSVA (gene set variation analysis) score stimulated by IL4/IL3 in the human skin, making GSVA score more normal[1]. JAK-IN-33 (59 μM, 40 h) has acceptable stability in the human skin, and can be effectively applied in human skin[1]. JAK-IN-33 (0.324 μL, 40 h) significantly inhibits the expression of TARC and two AD (atopic dermatitis) relevant biomarkers MMP12 and Eotaxin 3 in the Franz cells[1]. JAK-IN-33 is rapidly inactivated in the liver and is expected to have a better targeted systemic safety profile after topical application compares to oral JAK inhibitors repurposed for topical ues. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Real Time qPCR[1]

Cell Line:	Franz
Concentration:	0.324 μL
Incubation Time:	40 h
Result:	Significantly inhibited the expression of TARC, MMP12 and Eotaxin 3.

REFERENCES

[1]. Thoma G, Decoret O, et al. Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood. J Med Chem. 2023;66(21):15042-15053.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA